written on 13.05.2014

AstraZeneca trumpets diabetes duo's victory in Phase III


While its top executives were prepping for a hearing on Pfizer's megamerger offer, AstraZeneca rolled out new data from a diabetes trial. The verdict? A combination of the company's two diabetes pills, Onglyza and Farxiga, bested either drug alone.